Table 4.
Median time‐to‐event results by baseline hepatic function for all treatment regimens and individual treatment regimens, rwTTD and OS
| Normal | Moderate or severe dysfunction | |||
|---|---|---|---|---|
| Outcome and treatment regimen | Events/n | Median (95% CI), mo | Events/n | Median (95% CI), mo |
| rwTTD of ICI | ||||
| All | 1,299/1,669 | 2.5 (2.3–2.8) | 37/48 | 1.4 (0.5–2.1) |
| Ipilimumab | 502/528 | 2.1 (2.1–2.1) | 13/14 | 0.4 (0.0–n/a) |
| Ipi + nivolumab | 214/339 | 4.0 (3.3–5.6) | 9/12 | 0.7 (0.0–n/a) |
| Nivolumab | 182/332 | 6.2 (5.3–8.3) | 7/9 | 0.5 (0.0–n/a) |
| Pembrolizumab | 289/470 | 5.5 (4.6–7.1) | 6/13 | n/a (1.4–n/a) |
| OS | ||||
| All | 694/1,669 | 20.3 (18.0–23.5) | 25/48 | 4.7 (2.0–n/a) |
| Ipilimumab | 326/528 | 14.4 (12.2–16.7) | 10/14 | 2.5 (1.6–n/a) |
| Ipi + nivolumab | 110/339 | 29.4 (19.9–n/a) | 6/12 | 17.2 (2.1–n/a) |
| Nivolumab | 104/332 | 33.0 (18.2–n/a) | 5/9 | 1.0 (0.8–n/a) |
| Pembrolizumab | 154/470 | 27.8 (20.7–n/a) | 4/13 | n/a (4.7–n/a) |
For the median estimate, n/a occurred when <50% of the cohort had the event of interest. For 95% CI bounds, this occurred either when there were too few events or because the upper confidence limit is <50%.
Abbreviations: CI, confidence interval; Ipi, ipilimumab; OS, overall survival; n/a, result not calculable; rwTTD, real‐world time to treatment discontinuation.